InvestmentMay 4, 2026, 04:15 PM
Acurx Pharma Registers 1.3M Shares for Resale; May Get $4.7M More
AI Summary
Acurx Pharmaceuticals filed an S-1 registration statement to register 1,300,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC, under a pre-existing Purchase Agreement. The company may receive up to an additional $4.7 million from Lincoln Park, supplementing the $7.3 million already received. This filing also highlights a recent $2.5 million registered direct offering and a new clinical development initiative for ibezapolstat in recurrent C. difficile infection, alongside details of a prior reverse stock split.
Key Highlights
- Acurx Pharmaceuticals registered 1,300,000 common shares for resale by Lincoln Park Capital Fund, LLC.
- The company may receive up to $4.7 million in additional gross proceeds from Lincoln Park under the Purchase Agreement.
- Acurx previously received $7.3 million from sales to Lincoln Park under the same agreement.
- On April 15, 2026, Acurx completed a registered direct offering of 816,068 shares and pre-funded warrants for $2.5 million gross proceeds.
- A concurrent private placement issued warrants to purchase 1,650,170 shares at an exercise price of $2.78.
- Acurx announced a new clinical trial program for ibezapolstat in recurrent C. difficile infection (rCDI) with a pilot trial enrolling up to 20 patients.
- A 1-for-20 reverse stock split was effected on August 4, 2025.
- As of April 20, 2026, there were 4,278,492 shares of common stock outstanding.
Price Impact
More from ACXP